Compare AbbVie Inc (ABBV) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Schlumberger NV — how do they compare? AbbVie Inc trades at $253.81 (market cap $449.91B), while Schlumberger NV trades at $47.03 (market cap $69.40B). The key difference: AbbVie Inc is far larger — about 6.5× Schlumberger NV's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SLB | |
|---|---|---|
Market Cap | $449.91B | $69.40B |
Sector | Health | Energy |
52-Week High | $261.07 | $58.01 |
52-Week Low | $184.85 | $31.72 |
Enterprise Value | $513.38B | $77.62B |
Dividend Yield | 2.72% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SLB trades at $46.42, up 2.86% today, amid a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.52, exceeding the $0.508 estimate, and holds a strong analyst consensus with a $63.00 price target. Recent news highlights a seven-year digital innovation contract in Kuwait, expanding its energy technology footprint. Cash flow from operations remains robust at $6.49B for 2025, though net cash flow was negative due to significant financing activities.
The outlook is cautiously optimistic, supported by solid fundamentals and growth initiatives in digital and AI, but faces headwinds from oil price volatility and a recent decline in net income margin to 9.26%. The stock presents a potential opportunity given its valuation discounts to analyst targets, though macroeconomic risks and sector cyclicality warrant attention.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
